Products for Research Use Only
RegisterLogin

Fezagepras

CAT: 0804-HY-100775A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-100775A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fezagepras (Setogepram) acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84[1]. Fezagepras decreases renal, liver and pancreatic fibrosis[1][2]. Fezagepras exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions[2].
CAS Number
1002101-19-0
Product Name Alternative
Setogepram; PBI-4050
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Free Fatty Acid Receptor; GPR84
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/setogepram.html
Purity
99.38
Solubility
DMSO : 60 mg/mL (ultrasonic; warming)
Smiles
O=C(CC1=CC=CC(CCCCC)=C1)O
Molecular Formula
C13H18O2
Molecular Weight
206.28
Precautions
H302, H312, H332
References & Citations
[1]Li Y, et al. Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018 May 17;3 (10) . pii: 120365.|[2]Grouix B, et al. PBI-4050 Reduces Stellate Cell Activation and Liver Fibrosis through Modulation of Intracellular ATP Levels and the Liver Kinase B1/AMP-Activated Protein Kinase/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2018 Oct;367 (1) :71-81.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
MBS5767593Fezagepras
GTR19205202-01Fezagepras sodium

Popular Products